Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Peihong WangYvyin ZhangRufang XiangJie YangYanli XuTingfen DengWei ZhouCaixia WangXinhua XiaoShunqing WangPublished in: Cancer research (2024)
Foretinib exhibits superior efficacy to approved drugs in AML with FLT3-ITD mutations and retains activity in AML with secondary FLT3 mutations that mediate resistance to clinical FLT3 inhibitors.